Research Articles | Page 28 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia Apr 2021 Transplantation and Cellular Therapy Aplastic Anemia, Graft Versus Host Disease (GVHD)
Epidemiology and Pathogenesis of Myelodysplastic Syndrome May 2023 The Cancer Journal Myelodysplastic Syndromes (MDS)
Eltrombopag in children with severe aplastic anemia Apr 2021 Pediatric Blood & Cancer Aplastic Anemia, Pediatric
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution Apr 2019 Blood Aplastic Anemia
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) Jun 2023 Journal of Clinical Oncology Myelodysplastic Syndromes (MDS)
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) Oct 2023 Journal of Clinical Oncology Myelodysplastic Syndromes (MDS)
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis Dec 2023 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Jun 2023 Lancet Myelodysplastic Syndromes (MDS)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Jul 2023 Lancet Myelodysplastic Syndromes (MDS)